1-8 of 8
Teresa O'Brien
Close
Sort by
Journal Articles

Retrospective Study Evaluating Effect of Voxelotor Treatment on Acute Care Utilization during the Peak of COVID-19

Shivani Rao, Nicole K. Yun, James L. Coggan, Peter Wu, Teresa O'Brien, Katherine Barnett, Sean O'Mahony, Ramandeep Kaur, Christopher Bruti, Celine Goetz, Jerome J Martin, Sefer Gezer, Parameswaran Venugopal, Shivi Jain
Journal: Blood
Blood (2021) 138 (Supplement 1): 4179.
https://doi.org/10.1182/blood-2021-151985
Published: 2021
Journal Articles

Impact of Crizanlizumab on Acute Medical Care Utilization in the Height of the COVID-19 Pandemic

Shivani Rao, Nicole K. Yun, James L. Coggan, Peter Wu, Teresa O'Brien, Katherine Barnett, Sean O'Mahony, Ramandeep Kaur, Christopher Bruti, Celine Goetz, Jerome J Martin, Sefer Gezer, Parameswaran Venugopal, Shivi Jain
Journal: Blood
Blood (2021) 138 (Supplement 1): 4178.
https://doi.org/10.1182/blood-2021-151913
Published: 2021
Journal Articles

Update on a Prospective Study Evaluating the Safety and Efficacy of Combination Therapy with Fludarabine, Mitoxantrone and Rituximab Followed by Yttrium-90 Ibritumomab Tiuxetan and Maintenance Rituximab as Front Line Therapy for Patients with Indolent Lymphomas

Reem Karmali, MD, Mohamad Kassar, MD, Antonio M. Jimenez, MD, Parameswaran Venugopal, MD, Jamile M. Shammo, MD, Henry C. Fung, FRCP, MD, Robert Bayer, MD, Teresa O'Brien, Stephanie Gregory, MD
Journal: Blood
Blood (2010) 116 (21): 3946.
https://doi.org/10.1182/blood.V116.21.3946.3946
Published: 2010
Journal Articles

Phase II Study of 2-Weekly CHOP+Rituximab Followed by Yttrium-90 Ibritumomab Tiuxetan (Zevalin) In Patients with Previously Untreated Diffuse Large B Cell Lymphoma (DLBCL): Final Analysis

Reem Karmali, MD, Andrew Manson, Katherine Bueschel, MD, Kathryn Shell, Stephanie A. Gregory, MD, Teresa O'Brien, Jamile M. Shammo, MD, Melissa L Larson, MD, Parmeswaran Venugopal, MD
Journal: Blood
Blood (2010) 116 (21): 3947.
https://doi.org/10.1182/blood.V116.21.3947.3947
Published: 2010
Journal Articles

Tolerability of 2-Weekly CHOP+Rituximab Followed by Yttrium-90 Ibritumomab Tiuxetan (Zevalin) In Patients with Previously Untreated Diffuse Large B Cell Lymphoma (DLBCL): Final Analysis

Andrew Manson, Reem Karmali, MD, Irene Dehghan-Paz, MD, Eduardo Braun, MD, Teresa O'Brien, Stephanie A. Gregory, MD, Jamile M. Shammo, MD, Melissa L Larson, MD, Parmeswaran Venugopal, MD
Journal: Blood
Blood (2010) 116 (21): 4918.
https://doi.org/10.1182/blood.V116.21.4918.4918
Published: 2010
Journal Articles

A Novel Approach to the Treatment of Early Stage Hodgkin Lymphoma with a Mitoxantrone-Based Regimen Followed by Involved Field Radiotherapy: A 12 Year Follow up

Arlene Dawravoo, MD, Neel B. Shah, MD, Teresa O'Brien, Stephanie A. Gregory, MD, Parmeswaran Venugopal, MD
Journal: Blood
Blood (2010) 116 (21): 4901.
https://doi.org/10.1182/blood.V116.21.4901.4901
Published: 2010
Journal Articles

ESHAP with Rituximab Is Highly Efficacious with Durable Responses in Patients with Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma.

Rekha R. Threja, MD, Parameswaran Venugopal, MD, Stephanie A. Gregory, MD, Teresa O’Brien, RN, Elena Bogdanova
Journal: Blood
Blood (2005) 106 (11): 4787.
https://doi.org/10.1182/blood.V106.11.4787.4787
Published: 2005
Journal Articles

An Attempt to Enhance the Efficacy of Fludarabine, Mitoxantrone, Rituxan (FMR) with GM-CSF Priming: A Phase II Study.

Stacey E. Ban, MD, Parameswaran Venugopal, MD, Jamile M. Shammo, MD, Sari Enschede, MD, Solomon Adler, MD, Teresa O’Brien, RN, Stephanie A. Gregory, MD
Journal: Blood
Blood (2004) 104 (11): 4829.
https://doi.org/10.1182/blood.V104.11.4829.4829
Published: 2004